

## Notice from the Executive Officer: Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program

**December 14, 2017**

Effective **December 21, 2017**, Erelzi (etanercept) will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients.

Erelzi will be listed on the ODB Formulary/Comparative Drug Index (Formulary) as a Limited Use (LU) benefit for the following indications:

- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Polyarticular Juvenile Idiopathic Arthritis

Details of the LU criteria will also be posted in the December 2017 Formulary update which can be found on the ministry's website at:

[http://www.health.gov.on.ca/en/pro/programs/drugs/odbf\\_eformulary.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx)

To further inform healthcare providers and patients, we have also included a Frequently Asked Questions (FAQs) document for reference purposes.

### **Additional Information:**

#### **For pharmacies:**

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

#### **For all other Health Care Providers and the Public:**

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.